Laura Sutcliffe
Stock Analyst at UBS
(1.22)
# 3,594
Out of 4,914 analysts
6
Total ratings
50%
Success rate
-5.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Sutcliffe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RMD ResMed | Maintains: Buy | $290 → $285 | $276.61 | +3.03% | 1 | Apr 24, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $21 → $22 | $13.50 | +62.96% | 2 | Jan 27, 2025 | |
| ARGX argenx SE | Initiates: Buy | $390 | $594.87 | -34.44% | 1 | Jun 18, 2021 | |
| GLPG Galapagos NV | Downgrades: Neutral | n/a | $32.50 | - | 2 | Dec 20, 2019 |
ResMed
Apr 24, 2025
Maintains: Buy
Price Target: $290 → $285
Current: $276.61
Upside: +3.03%
Telix Pharmaceuticals
Jan 27, 2025
Maintains: Buy
Price Target: $21 → $22
Current: $13.50
Upside: +62.96%
argenx SE
Jun 18, 2021
Initiates: Buy
Price Target: $390
Current: $594.87
Upside: -34.44%
Galapagos NV
Dec 20, 2019
Downgrades: Neutral
Price Target: n/a
Current: $32.50
Upside: -